This document advertises a webinar from Computist Bio-Nanotech about designing small molecule protein-protein interaction inhibitors through computational design. The webinar will discuss using computational methods to discover drug compounds that target disease proteins, with examples of designing inhibitors for the Ras/Raf interaction. Computational design could accelerate drug discovery by designing molecules with known modes of action, improving compounds, and making previously difficult targets feasible to drug.
Our first webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the state of play for Complex Medicine and highlights the potential opportunity for the UK.
Prof Peter Simpson, Medicines Discovery Catapult
This presentation was given at a recent OHE Lunchtime Seminar by Kevin Outterson of the Boston University school of Law and Chatham House. It addresses the increasingly critical issue of antimicrobial resistance and the need for new antibiotics. This presentation identifies practices and norms that seem to fight against new antibiotics and the appropriate use of both new and existing one, reviews collaborative international efforts to develop a series of "design questions" that must be answered if efforts are to be effective, and identifies several functional areas that must be part of any new approach.
For other important OHE research and activities that address this topic, please see http://news.ohe.org/category/innovation/countering-amr/
How True Open Innovation TM and its global network can expand the opportunity for drug development by increasing efficiency and decreasing costs
Luca Rastelli, PhD
Boston Strategics Corporation
October, 2013
Our first webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the state of play for Complex Medicine and highlights the potential opportunity for the UK.
Prof Peter Simpson, Medicines Discovery Catapult
This presentation was given at a recent OHE Lunchtime Seminar by Kevin Outterson of the Boston University school of Law and Chatham House. It addresses the increasingly critical issue of antimicrobial resistance and the need for new antibiotics. This presentation identifies practices and norms that seem to fight against new antibiotics and the appropriate use of both new and existing one, reviews collaborative international efforts to develop a series of "design questions" that must be answered if efforts are to be effective, and identifies several functional areas that must be part of any new approach.
For other important OHE research and activities that address this topic, please see http://news.ohe.org/category/innovation/countering-amr/
How True Open Innovation TM and its global network can expand the opportunity for drug development by increasing efficiency and decreasing costs
Luca Rastelli, PhD
Boston Strategics Corporation
October, 2013
Accelerating multiple medicinal chemistry projects using Artificial Intellige...Al Dossetter
The technical methods and results of Matched Molecular Pair Analysis (MMPA) applied from a small, individual assay scale through large pharma scale, to multiple pharma data sharing scale have been published and reviewed. The drive behind these efforts has been to derive a medicinal chemistry knowledge base (i.e. definitive textbook) that can be applied to drug discovery projects. The aim is to greatly decrease the time in lead identification and optimization by the synthesis of fewer compounds. Such a system suggests compound designs to expert chemists to triage; such a process is Artificial Intelligence (AI). Given this context, how does this work on projects? How do the chemists make decisions? What are the results? The talk will answer these questions through project examples where MMPA has been applied and how this led to drug candidates. The projects disclosed are from multiple organisations and describe Cathepsin K inhibitors, Glucokinase Inhibitors, 11β-Hydroxysteroid Dehydrogenase Type I Inhibitors (11β-HSD1), Ghrelin inverse antagonists and Tubulin Polymerization inhibitors. An overview of MMPA will be presented and each project will be briefly described with a focus on how the chemists used MMPA to understand SAR and design compounds. The impact of project progress to CD will be quantified.
Pistoia Alliance datathon for drug repurposing for rare diseasesPistoia Alliance
As part of the Pistoia Alliance Centre of Excellence for AI in Life Sciences, we are running a datathon.
Rare Disease Drug Repurposing Datathon is your chance to advance knowledge on rare diseases and illustrate best practices in data science. Are you ready to help make a difference — and to showcase your organization’s data science work and skills?
Practical Drug Discovery using Explainable Artificial IntelligenceAl Dossetter
How to build AI systems to enable the drug hunting medicinal chemist in their day-to-day work. Levels are AI are described and the meaning and context Explainable AI to medicinal chemists. Six medicinal chemist projects are described, as well as Matched Molecular Pair Analysis (MMPA), Machine Learning and Permutative MMPA. In each case how a system can be built to drill back to chemical sub-structures so effective decisions can be made.
Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectivene...Office of Health Economics
In this presentation, OHE's Pistollato explains why it is important to consider price changes after marketing in CEA analysis and presents an approach for doing so.
- Discover new methods for managing clinical next-gen data with insights from Pfizer, Boston Children’s Hospital and AstraZeneca
- Uncover and critique the latest technologies out there for you to use in clinical trials. Mayo Clinic, Merck and Harvard Medical School let you into their trade secrets
- Hear the genomics strategies that Roche, Millennium and Regeneron are using for discovery and validation of clinically actionable biomarkers
-Bristol-Myers Squibb, Takeda and Partners Healthcare the role that NGS can play when implementing an effective strategy in the lab to speed up CDx development
- Learn how to integrate molecular details into medical decision making, with fresh data from Washington University School of Medicine and Genzyme
Equity research presentation and investment pitch on the viability of Invitae Corporation as a potential company to include in our portfolio. Analyzed the business model, strategic outlook, and competitive positioning of Invitae Corporation within the pre-natal genetic diagnostic testing industry. Includes DCF valuation of Invitae Corporation. My partner and I rated Invitae Corporation as a strong buy.
Current Approaches in European Drug related Health Care Policy: Relative Effe...Johan Strömquist
Key note speech held by Prof Bengt Jönsson from Stockholm School of Economics and Chairman of the NDA HTA Advisory Board, at the ZonMw Congres Goed Gebruik Geneesmiddelen, 31st January 2013, on the topic of dealing with decision making under uncertainty for the reimbursement of medicines
Our first webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at Complex Medicine and articulates what the commercial opportunity could be.
David Cook, Blueberry Therapeutics
In this presentation, OHE's Mestre-Ferrandiz summarizes what is known about innovation, both challenges and incentives, and applies this to efforts to encourage the development of new antibiotics.
Metrics of success for medical publication plans: results of a global surveyClarinda Cerejo
This poster was created by a team from Cactus Life Sciences in collaboration with representatives from Astellas, Tokyo; Boehringer Ingelheim, Ingelheim; and Amgen, Thousand Oaks. It was presented at the 13th Annual Meeting of ISMPP, May 1-3, 2017.
This poster presents the results of an online survey that was conducted to determine what medical publication professionals from pharmaceutical, biotech, device companies (industry), and medical communication agencies (agency) consider as important measures of success of publication plans.
In this presentation, OHE's Shah explains what a QALY is, how NICE has used QALYs in its decisions, whether and when other factors might take priority -- e.g. in end-of-life situations, and the importance of systematically gathering and analysing public preferences about such exceptions.
Accelerating multiple medicinal chemistry projects using Artificial Intellige...Al Dossetter
The technical methods and results of Matched Molecular Pair Analysis (MMPA) applied from a small, individual assay scale through large pharma scale, to multiple pharma data sharing scale have been published and reviewed. The drive behind these efforts has been to derive a medicinal chemistry knowledge base (i.e. definitive textbook) that can be applied to drug discovery projects. The aim is to greatly decrease the time in lead identification and optimization by the synthesis of fewer compounds. Such a system suggests compound designs to expert chemists to triage; such a process is Artificial Intelligence (AI). Given this context, how does this work on projects? How do the chemists make decisions? What are the results? The talk will answer these questions through project examples where MMPA has been applied and how this led to drug candidates. The projects disclosed are from multiple organisations and describe Cathepsin K inhibitors, Glucokinase Inhibitors, 11β-Hydroxysteroid Dehydrogenase Type I Inhibitors (11β-HSD1), Ghrelin inverse antagonists and Tubulin Polymerization inhibitors. An overview of MMPA will be presented and each project will be briefly described with a focus on how the chemists used MMPA to understand SAR and design compounds. The impact of project progress to CD will be quantified.
Pistoia Alliance datathon for drug repurposing for rare diseasesPistoia Alliance
As part of the Pistoia Alliance Centre of Excellence for AI in Life Sciences, we are running a datathon.
Rare Disease Drug Repurposing Datathon is your chance to advance knowledge on rare diseases and illustrate best practices in data science. Are you ready to help make a difference — and to showcase your organization’s data science work and skills?
Practical Drug Discovery using Explainable Artificial IntelligenceAl Dossetter
How to build AI systems to enable the drug hunting medicinal chemist in their day-to-day work. Levels are AI are described and the meaning and context Explainable AI to medicinal chemists. Six medicinal chemist projects are described, as well as Matched Molecular Pair Analysis (MMPA), Machine Learning and Permutative MMPA. In each case how a system can be built to drill back to chemical sub-structures so effective decisions can be made.
Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectivene...Office of Health Economics
In this presentation, OHE's Pistollato explains why it is important to consider price changes after marketing in CEA analysis and presents an approach for doing so.
- Discover new methods for managing clinical next-gen data with insights from Pfizer, Boston Children’s Hospital and AstraZeneca
- Uncover and critique the latest technologies out there for you to use in clinical trials. Mayo Clinic, Merck and Harvard Medical School let you into their trade secrets
- Hear the genomics strategies that Roche, Millennium and Regeneron are using for discovery and validation of clinically actionable biomarkers
-Bristol-Myers Squibb, Takeda and Partners Healthcare the role that NGS can play when implementing an effective strategy in the lab to speed up CDx development
- Learn how to integrate molecular details into medical decision making, with fresh data from Washington University School of Medicine and Genzyme
Equity research presentation and investment pitch on the viability of Invitae Corporation as a potential company to include in our portfolio. Analyzed the business model, strategic outlook, and competitive positioning of Invitae Corporation within the pre-natal genetic diagnostic testing industry. Includes DCF valuation of Invitae Corporation. My partner and I rated Invitae Corporation as a strong buy.
Current Approaches in European Drug related Health Care Policy: Relative Effe...Johan Strömquist
Key note speech held by Prof Bengt Jönsson from Stockholm School of Economics and Chairman of the NDA HTA Advisory Board, at the ZonMw Congres Goed Gebruik Geneesmiddelen, 31st January 2013, on the topic of dealing with decision making under uncertainty for the reimbursement of medicines
Our first webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at Complex Medicine and articulates what the commercial opportunity could be.
David Cook, Blueberry Therapeutics
In this presentation, OHE's Mestre-Ferrandiz summarizes what is known about innovation, both challenges and incentives, and applies this to efforts to encourage the development of new antibiotics.
Metrics of success for medical publication plans: results of a global surveyClarinda Cerejo
This poster was created by a team from Cactus Life Sciences in collaboration with representatives from Astellas, Tokyo; Boehringer Ingelheim, Ingelheim; and Amgen, Thousand Oaks. It was presented at the 13th Annual Meeting of ISMPP, May 1-3, 2017.
This poster presents the results of an online survey that was conducted to determine what medical publication professionals from pharmaceutical, biotech, device companies (industry), and medical communication agencies (agency) consider as important measures of success of publication plans.
In this presentation, OHE's Shah explains what a QALY is, how NICE has used QALYs in its decisions, whether and when other factors might take priority -- e.g. in end-of-life situations, and the importance of systematically gathering and analysing public preferences about such exceptions.
Small molecule inhibitors of PI4 KinaseDavid Andrews
Potent, selective small molecule inhibitors of type III phosphatidylinositol-4-kinase α- and β- and their effects on phosphatidylinositol signalling. The importance of small molecule probes to help us understand cellular pathways in cancer
Community Oncology Clinical Debates: Advanced Melanoma
Downloadable slide decks are a great tool for self study and teaching purposes. They are non-certified resources available to enhance your knowledge.
Review a downloadable slide deck by Antoni Ribas, MD, PhD, covering the most clinically relevant new data reported from Community Oncology Clinical Debates: Advanced Melanoma.
Target Audience
This educational activity has been designed to meet the unique learning needs of oncologists involved in the treatment of patients with advanced melanoma.
Disclaimer
This slide deck in its original and unaltered format is for educational purposes and is current as of June 2012. All materials contained herein reflect the views of the faculty, and not those of IMER, the CME provider, or the commercial supporter. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. Readers should not rely on this information as a substitute for professional medical advice, diagnosis, or treatment. The use of any information provided is solely at your own risk,
and readers should verify the prescribing information and all data before treating patients or employing any therapeutic products described in this educational activity.
Introduction to Targeted Therapies in OncologyMohamed Abdulla
Describes the molecular background which represents the core for developing targeted therapies against specific biological events in malignant cellular clones.
Dr. Michael Davies presents the latest information on targeted melanoma therapies at the MRF's Patient Symposium at MD Anderson Cancer Center on January 31, 2015.
Thomas Willkens-El impacto de las ciencias ómicas en la medicina, la nutrició...Fundación Ramón Areces
El 29 de marzo de 2016 celebramos un Simposio Internacional sobre el 'Impacto de las ciencias ómicas en la medicina, nutrición y biotecnología'. Organizado por la Fundación Ramón Areces en colaboración con la Real Academia Nacional de Medicina y BioEuroLatina, abordó cómo un mejor conocimiento del genoma humano está permitiendo notables avances hacia una medicina de precisión.
We have 13 research and development projects within:
• Research
• Oncology
• Respiratory, Inflammation and Autoimmunity
• Cardiovascular and Metabolic Disease
• Antibody Discovery and Protein Engineering
• Pathology
• Biopharmaceutical Development
• Cell Culture and Fermentation Sciences
• Formulation Sciences
• Analytical Biotechnology Science
160929 roche presentation molecule to businessSMBBV
Roche, How to deal with the affordability of oncology drugs?From personalised medicine to personalised reimbursement models. Presentation by Jeroen van Dijk during 'From Molecule to Business' event by SMB Life Sciences and Health Valley at NovioTechCampus, Nijmegen, The Netherlands on September 29, 2016.
PAREXEL Early Phase Clinical Research Services experts discuss developing trends in drug development including adaptive trials design, real-world data and biomarkers.
There is growing recognition that HTA and contracting systems for antimicrobials need to be adapted to help fight the threat of antimicrobial resistance (AMR), but there is little agreement on how. This poster reports findings from a literature review, expert interviews and face-to-face discussions at a Forum on the current HTA and payment systems for antibiotics across Europe and a number of recommendations for adapting these systems to respond to the challenges of AMR.
Author(s) and affiliation(s): Margherita Neri (OHE) Grace Hampson (OHE) Christopher Henshall (OHE visiting fellow, independent consultant) Adrian Towse (OHE)
Event: HTAi annual conference 2019
Date: 18/06/2019
Location: Cologne, Germany
Adrian Towse's slides from a session will exploring how the benefits of antibiotics can best be captured in HTA, and how we should pay for them when their value may depend on restricting their use.
Author(s) and affiliation(s): Adrian Towse, Office of Health Economics
Conference/meeting: Health Technology Assessment International (HTAi) 2018
Location: Vancouver, Canada
Date: 03/06/2018
Our second webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at developing the assay cascade for complex medicines.
Tilly Bingham, Concept Life Sciences
This is a presentation to the Australian Society for Antimicrobials (ASA) meeting in Melbourne, 27th February 2020. The presentation draws on research by OHE, funded by the Wellcome Trust, on innovative HTA methods and contracting for antibiotics. It proposes a subscription model delinking the use of new antibiotics from payments to developers for making the products available. It provides an update on UK (NICE and NHSE) plans to introduce a subscription model and suggests that Australia could also pilot such an approach.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
The Gram stain is a fundamental technique in microbiology used to classify bacteria based on their cell wall structure. It provides a quick and simple method to distinguish between Gram-positive and Gram-negative bacteria, which have different susceptibilities to antibiotics
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Webinar: Discovering Small Molecule Protein-Protein Interaction Inhibitors through Computational Drug Design
1. COMPUTIST
BIO-NANOTECH
DESIGNING THE RIGHT DRUG COMPOUND FOR THE RIGHT DISEASE TARGET
Live Webinar November 16 - 19, 2015
Discovering Small Molecule Protein-Protein Interaction Inhibitors
through Computational Design
Watch the webinar http://www.computistresearch.com/webinar.html